Business Wire - A Professional Thought Leader Analysis of Non-Interventional Cardiology and Major Industry Drugs
DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/research/ce5f70/thought_leader_ins) has announced the addition of the “Thought Leader Insight & Analysis: Non-Interventional Cardiology” report to their offering.
This report provides in-depth analysis of the market and pipeline from the perspective of global thought leaders.
Related Results
Research and Markets: Benchmark Abbotts Performance Against Key Rivals In The…
Drug challenge
JAPANESE NEWSPAPER HIGHLIGHTS - AUG 23, 2004.
Hypertensive drug classes: brand names only
Combination hypertension drug approved
This report includes discussions with seven US-based non-interventional cardiologists immediately after the 2008 meeting of the American College of Cardiology. Topics of discussion were driven by the Panelists. The umbrella theme for ACC2008 was that having an effect on attributes such as BP or LDL reduction, HDL elevation and even atherosclerotic plaque burden is nice, but having an effect on a hard outcome is compelling. The subplot for the meeting was the litany of trials that didn’t quite live up to expectations. Ironically, in the face of this disappointment it was JUPITER, a trial that wasn’t even presented, that created the most positive buzz.
Panelists provided insight and perspective on:
- “Evil Pharma” or Grandstanding Editorial Boards?
- Combination trials: ENHANCE, ONTARGET, ACCOMPLISH, ALLAY and others. Which combinations are “better”?
- Does how you change matter more than if you change LDL or HDL levels? Lipitor vs. Crestor: Is “more potent” better? Fibrates? Niacin?
- Statins only lower the risk of a CV event by 30%. Is CIMT a meaningful surrogate marker?
- Which are idiosyncratic properties of a specific agent? Which are the class effects?
- CETPs: torcetrapib vs. anacetrapib vs. R1658?
- Renin inhibitors: aliskiren in combination withO
- Can Bystolic (nebivolol) be differentiated?
Drugs discussed in this report include:
-Micardis (telmisartan; Boehringer-Ingelheim / Bayer Schering),
-Crestor (rosuvastatin; AstraZeneca),
-Lipitor (atorvastatin; Pfizer),
-Vytorin (ezetimibe atorvastatin;
-Schering-Plough / Merck),
-torcetrapib (Pfizer),
-RO4607381 (R1658; JTT-705; Roche / Japan Tobacco),
-anacetrapib (Merck),
-Tekturna (aliskiren; Novartis),
-aliskiren valsartan (Novartis),
-Lotrel (benazepril amlodipine; Novartis),
- Exforge (valsartan amlodipine; Novartis),
-Caduet (atorvastatin amlodipine; Pfizer),
-Bystolic (nebivolol; Forest / Mylan),
-Actos (pioglitazone; Takeda),
-Tricor / Lipanthyl (fenofibrate; Abbott / Solvay),
-Cordaptive / Tredaptive (niacin laropiprant; Merck),
-Niaspan (niacin; Abbott)
Key Topics Covered:
- Bulleted Highlights
- Key Findings
- Hard Outcomes
- Treating CAD vs. Treating Lipid Levels
- Genomics / Biomarkers
- Pharmacotherapy
- ARBs
- Statins
- Renin Inhibitors
- Beta Blockers
- Fibrates
- Combinations
- Statin Niacin ; Statin Fibrate
- Thought-Leader Discussions
For more information visit http://www.researchandmarkets.com/research/ce5f70/thought_leader_ins
COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning
